Literature DB >> 12084265

Gene therapy for prostate cancer.

J R Gingrich1, R D Chauhan, M S Steiner.   

Abstract

Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spawned the concept of gene therapy. This relatively new field seeks to reverse or suspend the pathologic progression of a variety of diseases including the malignant transformation of prostatic epithelial cells. Initial clinical trials for prostate cancer have thus far shown gene therapy to be relatively safe, although definitive evidence of durable therapeutic efficacy remains to be demonstrated. In this article, recent preclinical research, current therapeutic strategies, and recent results of gene therapy clinical trials for the treatment of prostate cancer are reviewed.

Entities:  

Mesh:

Year:  2001        PMID: 12084265     DOI: 10.1007/s11934-001-0079-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  45 in total

1.  FDA halts all gene therapy trials at Penn.

Authors:  E Marshall
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

2.  Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation.

Authors:  R Anello; S Cohen; G Atkinson; S J Hall
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

3.  Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.

Authors:  D L Paielli; M S Wing; K R Rogulski; J D Gilbert; A Kolozsvary; J H Kim; J Hughes; M Schnell; T Thompson; S O Freytag
Journal:  Mol Ther       Date:  2000-03       Impact factor: 11.454

4.  Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization.

Authors:  K R Rogulski; M S Wing; D L Paielli; J D Gilbert; J H Kim; S O Freytag
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

Review 5.  Cancer gene therapy: hard lessons and new courses.

Authors:  R G Vile; S J Russell; N R Lemoine
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

6.  Adenovirus p16 gene therapy for prostate cancer.

Authors:  J A Allay; M S Steiner; Y Zhang; C P Reed; J Cockroft; Y Lu
Journal:  World J Urol       Date:  2000-04       Impact factor: 4.226

7.  Cytopathic effect of in situ gene therapy in prostate cancer.

Authors:  G Ayala; T M Wheeler; M Shalev; T C Thompson; B Miles; E Aguilar-Cordova; S Chakraborty; D Kadmon
Journal:  Hum Pathol       Date:  2000-07       Impact factor: 3.466

8.  A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

Authors:  J P Eder; P W Kantoff; K Roper; G X Xu; G J Bubley; J Boyden; L Gritz; G Mazzara; W K Oh; P Arlen; K Y Tsang; D Panicali; J Schlom; D W Kufe
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

9.  An uncertain role for p53 gene alterations in human prostate cancers.

Authors:  J D Brooks; G S Bova; C M Ewing; S Piantadosi; B S Carter; J C Robinson; J I Epstein; W B Isaacs
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

10.  Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer.

Authors:  S J Hall; S E Mutchnik; S H Chen; S L Woo; T C Thompson
Journal:  Int J Cancer       Date:  1997-01-17       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.